Ayala Pharmaceuticals, Inc. (ADXS)
Ayala Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Monmouth Junction, NJ, US. The stock last traded at $0.60, up 0.00% on the session, giving a market capitalisation of $25.7M. On trailing twelve-month figures it carries a trailing P/E of -0.08, a net margin of -369784.6%. Its beta of -4.03 implies it has historically moved less than the broad market.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology firm, focuses on developing and commercializing small molecule therapies for individuals battling rare tumors and aggressive cancers. Its primary drug candidates currently in development include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), an innovative, proprietary anti-metabolite designed for first-line treatment in acute myeloid leukemia patients who are considered unfit. The company is headquartered in Wilmington, Delaware.
Ayala Pharmaceuticals, Inc. is most often compared with the following Healthcare names: